| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5699207 | Clinical Oncology | 2011 | 6 Pages |
Abstract
Our results show a good response of recurrent medulloblastoma after interstitial brachytherapy. High rates of tumour remission were yielded with low rates of treatment-related morbidity. Thus, 125I seed brachytherapy should be considered as a treatment option for recurrent medulloblastoma.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
F. El Majdoub, T. Simon, M. Hoevels, F. Berthold, V. Sturm, M. Maarouf,